January 23, 2014—The federal government and drugmakers have made their final arguments in the industry’s lawsuit over the government regulation that lets certain rural and cancer hospitals access 340B discounts on orphan drugs when used for non-orphan indications.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register.
Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)